paclitaxel - CISMeF

Preferred Label : paclitaxel;

MeSH definition : A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.;

CISMeF synonym : Bristol-Myers brand of paclitaxel; Bristol-Myers squibb brand of paclitaxel; bull brand of paclitaxel; ivax brand of paclitaxel; lemery brand of paclitaxel;

MeSH hyponym : anzatax; paxene; praxel; onxol; NSC-125973; taxol; paclitaxel, (4 alpha)-Isomer; NSC 125973; NSC125973; Taxol A; Bris Taxol; Taxol, Bris;

Related MeSH term : 7-epi-Taxol; 7 epi Taxol;

MeSH CAS label : benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,1-2alpha,12aalpha,12balpha))-;

MeSH Related Number : paclitaxel, (4 alpha)-Isomer; 105454-04-4 ((4 alpha)-isomer); 33069-62-4;

Registry Number MeSH : 33069-62-4;

Related CAS MeSH : 105454-04-4 (Paclitaxel, (4 alpha)-Isomer);

Wikipedia link : https://en.wikipedia.org/wiki/Paclitaxel;

Is substance : O;

UNII : P88XT4IS4D;

Details

Origin ID

D017239;

UMLS CUI

C0144576;

ATC code(s)
- paclitaxel [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Pegylated Paclitaxel [NCIt concept]
CISMeF manual mappings
- Paclitaxel adverse reaction (disorder) [SNOMED CT concept]
- Paclitaxel poisoning (disorder) [SNOMED CT concept]
Currated CISMeF NLP mapping
- PACLitaxel [LOINC component]
- Paclitaxel [ICD-11 Extension code]
- Paclitaxel [SMS substance]
- Paclitaxel [NCIt concept]
- Paclitaxel (substance) [SNOMED CT concept]
- paclitaxel [SNOMED Notion]
Indexing information
- 1,7-dihydroxytaxinine [MeSH Supplementary Concept]
Pharmacological action(s)
- antineoplastic agents, phytogenic [MeSH Descriptor]
- tubulin modulators [MeSH Descriptor]
Record concept(s)
- 7-epi-Taxol [MeSH concept]
- NSC-125973 [MeSH concept]
- anzatax [MeSH concept]
- onxol [MeSH concept]
- paclitaxel [MeSH concept]
- paclitaxel, (4 alpha)-Isomer [MeSH concept]
- paxene [MeSH concept]
- praxel [MeSH concept]
- taxol [MeSH concept]
Related MeSH Supplementary Concept(s)
- (14)C-CNDR-29 [MeSH Supplementary Concept]
- 1-deoxypaclitaxel [MeSH Supplementary Concept]
- 10-O-acetyl-5'-hydroxybutitaxel [MeSH Supplementary Concept]
- 10-O-deacetylpaclitaxel 10-monosuccinyl ester [MeSH Supplementary Concept]
- 10-deacetoxy-7-deoxypaclitaxel [MeSH Supplementary Concept]
- 10-succinyl paclitaxel [MeSH Supplementary Concept]
- 12b-acetyloxy-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-12-(2,5-dimethoxybenzyloxy)-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl 3-(tert-butyloxycarbonyl)amino-2-hydroxy-5-methyl-4-hexaenoate [MeSH Supplementary Concept]
- 130-nm albumin-bound paclitaxel [MeSH Supplementary Concept]
- 2'-paclitaxel methyl 2-glucopyranosyl succinate [MeSH Supplementary Concept]
- 2-debenzoyl-2-(3-azidobenzyl)-10-propionyldocetaxel [MeSH Supplementary Concept]
- 3'-(4-azidophenyl)-3'-dephenylpaclitaxel [MeSH Supplementary Concept]
- 3-(2-nitrophenyl)propionic acid-paclitaxel [MeSH Supplementary Concept]
- 4-fluoropaclitaxel [MeSH Supplementary Concept]
- 6,6,8-trimethyl-4,4a,5,6,7,7a,8,9-octahydrocyclopenta(4,5)cyclohepta(1,2-c)-furan-4,8-diol 4-(N-acetyl-3-phenylisoserinate) [MeSH Supplementary Concept]
- 6,6,8-trimethyl-4,4a,5,6,7,7a,8,9-octahydrocyclopenta(4,5)cyclohepta(1,2-c)-furan-4,8-diol 4-(N-tert-butoxycarbonyl-3-phenylisoserinate) [MeSH Supplementary Concept]
- 7-(3-methyl-3-nitrosothiobutyryl)paclitaxel [MeSH Supplementary Concept]
- 7-deoxypaclitaxel [MeSH Supplementary Concept]
- 7-succinylpaclitaxel [MeSH Supplementary Concept]
- 7-xylosyl-10-deacetylpaclitaxel [MeSH Supplementary Concept]
- A-Z-CINN 310 [MeSH Supplementary Concept]
- AI-850 [MeSH Supplementary Concept]
- AT protocol [MeSH Supplementary Concept]
- AZ 10992 [MeSH Supplementary Concept]
- CQMU-0517 [MeSH Supplementary Concept]
- CQMU-0519 [MeSH Supplementary Concept]
- ET protocol [MeSH Supplementary Concept]
- HPMA copolymer-PTX-FK-ALN conjugate [MeSH Supplementary Concept]
- JCA112 [MeSH Supplementary Concept]
- Lx2-32c compound [MeSH Supplementary Concept]
- MAC321 [MeSH Supplementary Concept]
- MBT-0206 [MeSH Supplementary Concept]
- MP 264 [MeSH Supplementary Concept]
- MP 265 [MeSH Supplementary Concept]
- MTC-220 [MeSH Supplementary Concept]
- N-(2-hydroxypropyl)methacrylamide copolymer-paclitaxel conjugate [MeSH Supplementary Concept]
- NK105 [MeSH Supplementary Concept]
- ONCOFID-P [MeSH Supplementary Concept]
- PC protocol [MeSH Supplementary Concept]
- PET regimen [MeSH Supplementary Concept]
- TCF protocol [MeSH Supplementary Concept]
- TP protocol [MeSH Supplementary Concept]
- TXD 258 [MeSH Supplementary Concept]
- cyclotriphosphazene-paclitaxel conjugate [MeSH Supplementary Concept]
- docosahexaenoyl-paclitaxel [MeSH Supplementary Concept]
- folic acid-5-aminofluorescein-glutamic-paclitaxel [MeSH Supplementary Concept]
- folic acid-fluorescein-5(6)-isothiocyanate-arginine-paclitaxel [MeSH Supplementary Concept]
- genexol-PM [MeSH Supplementary Concept]
- isotaxel [MeSH Supplementary Concept]
- pacliex [MeSH Supplementary Concept]
- paclitaxel 2'-ethylcarbonate [MeSH Supplementary Concept]
- paclitaxel poliglumex [MeSH Supplementary Concept]
- paclitaxel-Angiopep-2 conjugate [MeSH Supplementary Concept]
- paclitaxel-EC-1 conjugate [MeSH Supplementary Concept]
- polilactofate [MeSH Supplementary Concept]
- poly(ethylene oxide)-block-polyphosphoester-graft-paclitaxel [MeSH Supplementary Concept]
- poly(gamma-glutamylcarbocysteine)paclitaxel [MeSH Supplementary Concept]
- poly(gamma-glutamylglutamine)paclitaxel [MeSH Supplementary Concept]
- triolimus [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- PACLitaxel [LOINC component]
- Paclitaxel [NCIt concept]
- Paclitaxel (substance) [SNOMED CT concept]
- Paclitaxel Preparation [NCIt concept]
- Product containing paclitaxel (medicinal product) [SNOMED CT concept]
- paclitaxel [ATC Code]
- paclitaxel [SNOMED Notion]
Validated automatic mappings to BTNT
- paclitaxel [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients